Reuters logo
BRIEF-GSK receives EU marketing authorisation for COPD drug Anoro
May 8, 2014 / 3:10 PM / 3 years ago

BRIEF-GSK receives EU marketing authorisation for COPD drug Anoro

May 8 (Reuters) - GlaxoSmithKline Plc :

* GSK receives EU marketing authorisation for Anoro

* Anoro (Umeclidinium/Vilanterol) gains marketing authorisation in Europe for treatment of COPD

* Licensed strength in europe is umec/vi 55mcg / 22mcg

* Theravance is obligated to make a milestone payment to GSK of $15 million following marketing authorisation for umec/vi by European Commission

* First launch is expected to take place in europe in Q2-3 2014 with additional launches to follow thereafter

* Further $15 million payment to GSK will follow launch of umec/vi in Europe Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below